Clinical Trial

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

Study acronym: ARES
Recruiting
View on ClinicalTrials.gov →
Summary
ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 9 locations 2026-05-02
Trial Details
NCT Number NCT07399665
Lead Sponsor AstraZeneca
Conditions Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma
Enrollment 110 participants
Start Date 2025-12-25
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13